Women in British Columbia will no longer have to wait weeks to find out if their abnormal mammography results are cause for worry. The screening mammography program (SMP) at BC Cancer Agency is expanding the Fast Track referral system to provide all physicians in British Columbia with access to the program designed to reduce the time between an abnormal screening mammography result and access to further diagnostic investigation.

Cleveland BioLabs, Inc. announced that the first healthy volunteers have been dosed in the second human safety study for CBLB502, a drug under development for the treatment of Acute Radiation Syndrome (ARS). CBLB502 is being developed by Cleveland BioLabs under the FDA’s Animal Efficacy Rule to treat Acute Radiation Syndrome (ARS) or radiation poisoning from any exposure to radiation such as a nuclear or radiological weapon / dirty bomb, or from a nuclear accident.

For the full story, Click Here

Oraya Therapeutics, Inc. announced that enrollment is now underway for the first ever masked and sham-controlled study to demonstrate the efficacy and safety of radiation therapy for the treatment of wet age-related macular degeneration . The groundbreaking clinical trial is being conducted at seven European sites, and will include at least 150 patients, with approximately one third of those receiving a sham exposure and the remainder receiving radiation dosing of either 16 or 24 Gray.

For the full story, Click Here

Cleveland BioLabs, Inc. announced that the U.S. Patent and Trademark Office has issued US Patent No. 7,638,485 titled “Modulating Apoptosis” covering the method of protecting a mammal from radiation using flagellin or its derivatives, including CBLB502. This patent was already granted by the nine member countries of the Eurasian Patent Organization (EAPO), and two additional nations. Cleveland BioLabs has also filed two additional new patent applications related to Protectan technology in the U.S.

For the full story, Click Here